| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/717405/2012 (16.11.12) |
| Publication Date | 16/11/2012 |
| Content Type | News |
|
The European Medicines Agency (EMA), in November 2012, finalised a review into the supply chain for protamine-containing medicinal products and concluded that there would be no supply shortage for medicinal products containing protamine in the European Union (EU). Protamine sulphate is used to counteract the anticoagulant action of heparin in the treatment of bleeding resulting from heparin overdose. It is also used to neutralise the effect of heparin, particularly in cardiac surgery. |
|
| Source Link | http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/11/news_detail_001657.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
